442 related articles for article (PubMed ID: 26516212)
1. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.
Fernández-Santiago R; Carballo-Carbajal I; Castellano G; Torrent R; Richaud Y; Sánchez-Danés A; Vilarrasa-Blasi R; Sánchez-Pla A; Mosquera JL; Soriano J; López-Barneo J; Canals JM; Alberch J; Raya Á; Vila M; Consiglio A; Martín-Subero JI; Ezquerra M; Tolosa E
EMBO Mol Med; 2015 Dec; 7(12):1529-46. PubMed ID: 26516212
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients.
Tolosa E; Botta-Orfila T; Morató X; Calatayud C; Ferrer-Lorente R; Martí MJ; Fernández M; Gaig C; Raya Á; Consiglio A; Ezquerra M; Fernández-Santiago R
Neurobiol Aging; 2018 Sep; 69():283-291. PubMed ID: 29935433
[TBL] [Abstract][Full Text] [Related]
3. Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients.
Fernández-Santiago R; Merkel A; Castellano G; Heath S; Raya Á; Tolosa E; Martí MJ; Consiglio A; Ezquerra M
Clin Epigenetics; 2019 Jul; 11(1):108. PubMed ID: 31337434
[TBL] [Abstract][Full Text] [Related]
4. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease in a dish - Using stem cells as a molecular tool.
Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
Sandor C; Robertson P; Lang C; Heger A; Booth H; Vowles J; Witty L; Bowden R; Hu M; Cowley SA; Wade-Martins R; Webber C
Hum Mol Genet; 2017 Feb; 26(3):552-566. PubMed ID: 28096185
[TBL] [Abstract][Full Text] [Related]
7. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
[TBL] [Abstract][Full Text] [Related]
8. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
11. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
[TBL] [Abstract][Full Text] [Related]
12. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
[TBL] [Abstract][Full Text] [Related]
13. Phenotypical Differences in Neuronal Cultures Derived via Reprogramming the Fibroblasts from Patients Carrying Mutations in Parkinsonian Genes LRRK2 and PARK2.
Konovalova EV; Novosadova EV; Grivennikov IA; Illarioshkin SN
Bull Exp Biol Med; 2015 Oct; 159(6):772-5. PubMed ID: 26519280
[TBL] [Abstract][Full Text] [Related]
14. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
[TBL] [Abstract][Full Text] [Related]
15. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.
Sánchez-Danés A; Richaud-Patin Y; Carballo-Carbajal I; Jiménez-Delgado S; Caig C; Mora S; Di Guglielmo C; Ezquerra M; Patel B; Giralt A; Canals JM; Memo M; Alberch J; López-Barneo J; Vila M; Cuervo AM; Tolosa E; Consiglio A; Raya A
EMBO Mol Med; 2012 May; 4(5):380-95. PubMed ID: 22407749
[TBL] [Abstract][Full Text] [Related]
16. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
Schwab AJ; Ebert AD
Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.
Cooper O; Seo H; Andrabi S; Guardia-Laguarta C; Graziotto J; Sundberg M; McLean JR; Carrillo-Reid L; Xie Z; Osborn T; Hargus G; Deleidi M; Lawson T; Bogetofte H; Perez-Torres E; Clark L; Moskowitz C; Mazzulli J; Chen L; Volpicelli-Daley L; Romero N; Jiang H; Uitti RJ; Huang Z; Opala G; Scarffe LA; Dawson VL; Klein C; Feng J; Ross OA; Trojanowski JQ; Lee VM; Marder K; Surmeier DJ; Wszolek ZK; Przedborski S; Krainc D; Dawson TM; Isacson O
Sci Transl Med; 2012 Jul; 4(141):141ra90. PubMed ID: 22764206
[TBL] [Abstract][Full Text] [Related]
18. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
[TBL] [Abstract][Full Text] [Related]
20. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
